ALZN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alzamend Neuro Inc (ALZN) is not a good buy for a beginner investor with a long-term investment strategy. The stock is experiencing a significant downtrend, with bearish technical indicators, no positive trading signals, and weak financial performance. Additionally, there are no strong positive catalysts or influential figures supporting the stock.
The stock is in a strong bearish trend. The MACD is negatively expanding, RSI is at 24.028 indicating oversold conditions but no clear signal, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The price is significantly below key support levels (S1: 1.554, S2: 1.342), with no signs of recovery.
The Phase II trial results for AL001 show potential in treating Alzheimer's and other conditions, which could be a long-term positive catalyst.
The stock has dropped significantly (-22.28% in regular market hours, -3.33% post-market). Financial performance is weak, with negative net income and declining EPS. Technical indicators and trading trends are bearish, and there is no recent activity from hedge funds, insiders, or Congress.
In Q3 2026, revenue remained at 0 with no growth. Net income improved to -$2,198,991 (up 104.91% YoY), but EPS dropped significantly by -66.86% YoY to -0.58, indicating poor profitability.
No analyst rating or price target changes are provided. Wall Street sentiment is unclear, but the financial performance and technical indicators suggest a negative view.
